甲胎蛋白、人绒毛膜促性腺激素及非结合雌三醇在产前筛查中的临床意义
| 作者: |
1庞春玉,
1吴学礼
1 海口市妇幼保健院检验科，海口 570203 |
| 通讯: |
庞春玉
Email: pa3907524759@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2016.08.028 |
| 基金: | 海南省卫生厅科学研究课题, 琼卫 2013PT-36 |
摘要
目的：探讨甲胎蛋白、人绒毛膜促性腺激素及非结合雌三醇在产前筛查中的临床意义。方法：选取我院2014年12月至2015年6月孕周为15~20周的妊娠孕妇血清标本2 070例，予以产前甲胎蛋白、人绒毛膜促性腺激素及非结合雌三醇的检测，并且结合孕妇的年龄、孕周、体质量等因素，运用配套的仪器产前筛查风险软件统计唐氏综合症、18–三体综合征及神经管缺陷的风险比例，予以高危孕妇做详细确诊，并依据随访与诊断结果比较高危组与低危组甲胎蛋白、人绒毛膜促性腺激素、非结合雌三醇水平，及出生缺陷阳性确诊率，产前筛查孕妇的年龄分布与出生缺陷的筛查阳性率。结果：高危组甲胎蛋白水平显著高于低危组[(28.74±1.35) vs. (6.93±1.20) μg/L]，人绒毛膜促性腺激素水平显著高于低危组[(2.43±0.37) vs. (1.76±0.25) ng/L]，非结合雌三醇水平明显低于低危组[(5.35±1.23) vs. (7.26±1.14) μg/L]，两组比较差异明显(P<0.05)；≤35岁孕妇出生缺陷总筛查阳性率(4.27%)显著低于>35岁孕妇(26.24%)；高危组孕妇出生缺陷总确诊阳性率(7.14%)明显高于低危孕妇(0.21%)，两组比较差异显著。结论：甲胎蛋白、人绒毛膜促性腺激素及非结合雌三醇产前筛查能够有效筛查出生缺陷的概率，达到优生，值得推广运用。
关键词：
人绒毛膜促性腺激素
甲胎蛋白
非结合雌三醇
产前筛查
出生缺陷
The clinical significance of alpha-fetoprotein, human chorionic gonadotropin and unconjugated estriol in perinatal screening
CorrespondingAuthor: PANG Chunyu Email: pa3907524759@163.com
DOI: 10.3978/j.issn.2095-6959.2016.08.028
Abstract
Objective: To investigate the clinical significance of alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG) and unconjugated estriol (uE3) in perinatal screening. Methods: Selected 2 070 serum samples in pregnant women with gestational age of 15~20 weeks from December 2014 to June 2015 in our hospital, detected AFP, HCG and uE3 in prenatal testing, and combining with the age, gestational age, body weight and other factors, counted the risk ratio of Down syndrome, trisomy 18 and the proportion of risk of neural tube defects by supporting instrument risk prenatal screening software to diagnose in detail for high-risk women, and compared with AFP, HCG, and uE3 levels of birth defects and the positive rate of diagnosis in high- and low-risk group, age distribution of prenatal screening and the positive rate of screening for birth defects according to the results of diagnosis and follow-up. Results: The AFP in high-risk group was significantly higher than that in the low-risk group [(28.74±1.35) vs. (16.93±1.20) μg/L],
and HCG levels were significantly higher than that in the low risk group [(2.43±0.37) vs. (1.76±0.25) ng/L], uE3 levels were significantly lower than that in the low-risk group [(5.35±1.23) vs. (7.26±1.14) μg/L], the difference was significant (P<0.05); the total positive rate of screening for birth defects in ≤35-year-old pregnant women (4.27%) was significantly lower than those in the >35-year-old pregnant women (26.24%); the total positive rate of diagnosis of birth defects in high-risk group (7.14%) was significantly higher than that in the low-risk pregnant women (0.21%), the difference was significant. Conclusion: Prenatal screening AFP, HCG and uE3 can effectively increase the chance of birth defects, reach the eugenics; and it is worth to promote the use.
and HCG levels were significantly higher than that in the low risk group [(2.43±0.37) vs. (1.76±0.25) ng/L], uE3 levels were significantly lower than that in the low-risk group [(5.35±1.23) vs. (7.26±1.14) μg/L], the difference was significant (P<0.05); the total positive rate of screening for birth defects in ≤35-year-old pregnant women (4.27%) was significantly lower than those in the >35-year-old pregnant women (26.24%); the total positive rate of diagnosis of birth defects in high-risk group (7.14%) was significantly higher than that in the low-risk pregnant women (0.21%), the difference was significant. Conclusion: Prenatal screening AFP, HCG and uE3 can effectively increase the chance of birth defects, reach the eugenics; and it is worth to promote the use.